Semaglutide is one type of active ingredient in glucagon-like peptide-1 (GLP-1) receptor agonist drugs, widely known as type 2 diabetes treatment (Ozempic) and weight loss medication for obesity (Wegovy)
Understanding this potential side effect, its underlying causes, and practical management strategies can help patients navigate treatment more comfortably and make informed decisions about their weight management journey
You notice benefits faster while using lower total doses, making treatment both more effective and more efficient
Hypertrophy is simply an increase in the size of muslce cells
Patients experience significant weight loss, typically 10-15% of body weight. A1C levels drop, reducing long-term diabetes-related risks. Lower cholesterol and blood pressure levels, improving cardiovascular health
Current Treatment Options in Gastroenterology, 18 (1), 3342